APASL 2017 - Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians

MIMS Hepatology

Triple DAA combo containing ritonavir effective, safe for HCV GT1b in Asians

13 hours ago, Pearl Toh

A combination of the direct-acting antiviral agents (DAAs) ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) and dasabuvir (DSV) resulted in sustained virologic response at post-treatment week 12 (SVR12) in almost all Asian adult patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection without cirrhosis, according to the ONYX-I* study presented at the recent Asian Pacific Association for the Study of the Liver Annual Meeting (APASL 2017) held in Shanghai, China.

Continue reading...

Conference Coverage
Slides @ NATAP
Feb 21
ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered with Ribavirin in Asian Adults with Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis

Of Interest
AASLD
The Liver Meeting
Boston MA
November 2016
ONYX-I: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection - A Randomized, Double-Blind, Placebo-Controlled Study - (11/17/16)

ONYX-II: Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir Coadministered With Ribavirin in Asian Adults With Genotype 1b Chronic Hepatitis C Virus Infection and Compensated Cirrhosis - (11/17/16)

July 25, 2016

FDA approves a New Drug Application (NDA) for VIEKIRA XR™ (dasabuvir, ombitasvir, paritaprevir and ritonavir)